The Series C round financing will be used to fund a phase 3 trial of its lead drug, SER-109, intended to prevent the recurrence of Clostridium difficile infection. The drug is considered a biologic by the U.S. Food and Drug Administration. Early stage trial results showed that the use of the drug resulted in 29 out of 30 patients remaining infection-free for two months, according to the report.
More articles on gastroenterology:
ASGE, ACG update GI procedure quality indicators: 4 things to know
FDA approves Aer-O-Scope Colonoscope System
4 gastroenterologists on the move
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
